T cells require two distinct signals for optimal activation, an antigen -specific signal, provided by engagement of the T -cell receptor ( TCR ) and a second costimulatory signal mediated by engagement of CD28 with members of the B7 family. Although infiltrating T cells are present in many malignancies, they appear to be mostly anergic and do not attack the tumor, presumably because of the absence of activation and / or costimulatory signals. Here we describe a novel strategy for the in situ activation of tumor -specific T cells. We genetically modified T cells to secrete a bifunctional fusion protein, comprising the extracellular portion of B7 -1 fused to an anticarcinoembryonic antigen ( CEA ) diabody. In coculture with CEA + tumor cells autocrine and paracrine secretion of B7 -CEA provided a potent tumor -specific costimulatory signal to T cells in combination with a recombinant CEAÂCD3 bispecific diabody. B7 -CEA was also found to strongly enhance survival and tumor -specific activation of T cells expressing an anti -CEA TCR -based chimeric immune receptor ( CIR ) both when expressed in cis by the T cells themselves as well as in trans, when added to the culture medium. In the absence of costimulatory signals provided by the tumor, our strategy allows T cells to ''arm themselves'' by the production of tumor -specific costimulatory proteins. Sustained in situ production of such molecules, like the B7 -diabody fusion protein may create a favorable local environment for the activation and proliferation of tumor -reactive T cells and increase the tumoricidal activity of immunotherapeutic approaches targeting the TCR pathway.
T cells recognize antigen as peptide fragments presented in the context of major histocompatibility complex ( MHC ) molecules at the surface of cells. 1 However, although T-cell antigen receptor ( TCR ) signal transduction may be sufficient to activate antigen -primed T cells, under most circumstances TCR ligation alone is not sufficient to initiate an immune response. 2, 3 For optimal activation of naive T cells, subsequent autocrine -driven clonal expansion, and induction of effector functions, additional costimulatory signals are needed. 4 The interaction between the B7 family members (B7 -1; CD80, B7-2; CD86 ) on antigen -presenting cells ( APC ) with CD28 on T cells has been shown to play a key role in providing costimulation for the activation of T-cell effector functions. 5 Engagement of TCR in the absence of costimulation may result in the induction of specific T-cell unresponsiveness or anergy. Many tumors lack, have lost, or down -regulated surface expression of B7 and /or MHC and, thus, avoid Tcell responses. 6, 7 These observations have prompted strategies to avoid the induction of anergy in T cells. One strategy has been to provide B7 on the surface of tumor cells by ex vivo transfection with the B7 gene. 8 In animal models, the transfection with the B7 gene enhanced tumor immunogenicity, although it had little or no effect on the immunogenicity of poorly or nonimmunogenic tumors. 8, 9 Moreover, the provision of costimulation in vivo by genetically modified tumor cells is limited to a small fraction of the total tumor burden, and the reinfusion of ex vivo genemodified autologous tumor cells may present practical and ethical problems.
Instead of transfecting tumor cells ex vivo with costimulatory molecules, T-cell costimulation can be provided by antibody -based targeting. For example, we have shown that chimeric single -chain antibody fragment (scFv )-CD28 receptors could be stably expressed as functional cell surface receptors on T cells, and that antigen-specific costimulatory signals synergized with signals mediated through the native TCR or TCR -based chimeric immune receptors (CIRs) to produce maximal levels of IL -2. 10, 11 In the absence of natural costimulatory molecules, tumor-specific CD28 signals enhanced survival and proliferation of human primary T cells. 12 However, the major disadvantage of CIR -based approaches is that tumor-specific primary 13 and / or costimulatory signals 10, 14 are restricted to gene -modified T cells. 15 Another approach to provide B7 to tumor cells is based on the use of fusion proteins comprised of the extracellular CD28 binding domain of human B7 fused to a target cellspecific recognition domain. 16, 17 Chimeric B7 fusion proteins provide costimulatory signals that result in enhanced proliferation of primary T cells. 18 Improved B7 fusion constructs comprising exclusively variable Agrecognition domains of human origin and with higher affinity have been reported. 19 However, the therapeutic potential of exogenously administered B7 -antibody fusion proteins is potentially limited by their short half -life, and the often poor accessibility of solid -tumor sites to recombinant molecules. 20, 21 Here we have explored a strategy that could bypass these problems by the in situ production of soluble tumor-specific B7 molecules at the tumor site by cells that have preferential tumor-targeting properties, such as T cells and macrophages. Using a chimeric B7 -1 diabody construct directed against the colon carcinoma -specific marker anticarcinoembryonic antigen ( CEA ) we show that fusion proteins secreted from human producer T cells can provide effective and tumor-specific costimulation to retargeted T-cell effectors.
Materials and methods

Antibodies
The mAbs used included: OKT3 (mouse IgG 2a , Ortho Biotech, New Jersey, NJ ) specific for human CD3"; DAL -1 ( mouse IgG 1 ; Serotec, Oxford, UK ) specific for human CD80; 85A12 ( mouse IgG 1 ; Serotec ) specific for human CD66e; YTH 913.12 ( rat IgG 2b ; Serotec) specific for human CD28. Anti -myc (9E10) mAb ( mouse IgG 1 ) was from Sigma Biosciences ( St. Louis, MO ). For direct staining, the FITC -conjugated mAb UCHT-1 anti -human CD3" (mouse IgG 1 , DAKO, Copenhagen, Denmark ) and YTH 913.12 were used. The polyclonal antibodies used included an HRP -conjugated goat anti -mouse IgG ( Fc specific; Sigma Biosciences ) and an FITC -conjugated goat anti-mouse IgG ( chain specific ) ( Sigma Biosciences ).
Cells and culture conditions
Human embryonic kidney 293 cells (CRL -1573 ), human leukemic T cells, Jurkat clone E6 -1 (TIB-152 ), and human cervix carcinoma HeLa cells (CCL -2 ) were obtained from the American Type Culture Collection (Rockville, MD ). 293 cells were grown in DMEM supplemented with 10% (vol / vol ) heat -inactivated FCS, ( all from Life Technologies, Gaithersburg, MD ) referred as to DMEM complete medium ( DCM ). Jurkat and HeLa cells were maintained in RPMI-1640 ( Life Technologies ) supplemented with heat -inactivated 10% FCS, referred as to RPMI complete medium ( RCM ). The human gastric cancer cell line MKN45 18 was cultured in RCM. All cell lines were monitored routinely and found to be free of mycoplasma infection.
Expression and purification of the recombinant diabody TG1 was used for propagation of the plasmid pUC119MFE23 /OKT3 and the expression of antibody fragments. Soluble diabody was expressed as described 22 and purified from concentrated culture supernatant (SN ) by single-step IMAC. 23 
Construction of vectors
The plasmid ( pCEP4.huB7 -1 ) containing the leader region and the two extracellular domains of the human B7 -1 gene was kindly provided by RE Hawkins ( University of Manchester ). The plasmid pUC119B7 -1 / MFE -23 -euk was constructed by removing the HindIIIPml I fragment (containing the pelB prokaryotic leader segment ) from plasmid pUC119.B7 -1 /MFE -23 18 and inserting the pCEP4.huB7 -1 derived 117 bp HindIIIPml I fragment, containing the human B7 -1 leader segment. To construct the plasmids pLAV32 and pR32 the 1520 -bp HindIII -Not I fragment derived from the plasmid pUC119.B7-1/ MFE -23 -euk was cloned in pCEP4 or pREP9, respectively ( Invitrogen, San Diego, CA ). The plasmid pCEP4.CEA.TCR was constructed by inserting the anti -human CEA scFv antibody fragment ( MFE -23 ) as HindIII -Not I fragment into the vector pCEP4.NIP.TCR. 24 Cell transfections 293 cells were transiently transfected with pLAV32 plasmid using Lipofectamine (Life Technologies ). Supernatant was recollected at 48 hours and analyzed for B7 -CEA fusion protein expression by ELISA. To generate stable cell lines, pLAV32 transfected 293 cells ( 293.B7 ) were selected in DCM with 150 g /mL hygromycin B (Life Technologies ). Supernatants from stable transfected cell populations were recollected and analyzed for fusion protein secretion by ELISA. Jurkat cells were transfected with plasmids pLAV32 ( JurkatB7) or pCEP4.CEA.TCR (JurkatCEA ) using Superfect (Qiagen, Hilden, Germany ) and selected in RCM supplemented with 400 g/ mL hygromycin B. Hygromycin -resistant cells were visible after 3-4 weeks and analyzed by ELISA for B7 -CEA protein secretion. To generate double transfectants, cells expressing the chimeric anti-CEA -TCR molecule were transfected under the same conditions with plasmid pR32 (JurkatCEA.B7 ). After transfection, cells were grown in RCM supplemented with 400 g /mL hygromycin B and 2 mg /mL G -418 (Life Technologies ).
Flow cytometry
Cell surface staining was performed by standard direct immunofluorescence as described. 25 The expression of CD66e on HeLa and MKN45 cells was studied by indirect immunofluorescence using a mouse anti -human CEA mAb and an FITC -conjugated goat anti -mouse IgG. Dead cells were excluded from analysis using a combination of propidium iodide and forward light scatter. The samples were analyzed with an EPICS XL (Coulter Electronics, Hialeah, FL ).
Specificity ELISA
Human purified CEA (Sigma Biosciences ) was coated on microtiter plates at 2 g /mL in PBS at 48C overnight and
Cancer Gene Therapy Autocrine costimulation B Blanco et al after washing blocked with 4% BSA in PBS for 2 hours at 378C. Filtered cell -free SNs from transfected 293 or Jurkat cells were added and bound B7-CEA protein was detected with either anti -CD80 ( 10 g /mL ) or anti -myc (10 g/ mL ) mAbs and then with an HRP -conjugated goat antimouse IgG.
Functional studies
Nontransduced and stable transfected Jurkat ( JurkatB7 or JurkatCEA ) cells ( 5Â10 4 /well ) were stimulated in duplicate under various conditions in round -bottom 96-well microtiter plates with glutaraldehyde -inactivated target ( HeLa or MKN45 ) cells at different effector:target (E:T ) ratios or with varying amounts of plastic -immobilized CEA. Where indicated, neat or concentrated filtered cell -free SNs from 48 -hour cultures of either untransfected (Jurkat or 293) or stable transfected (JurkatB7 or 293.B7 ) cells were added. Purified recombinant MFE23 /OKT3 diabody was added at 1 g/ mL. As controls, effector cells were cultured in wells precoated with anti -CD3 mAb (10 g /mL ) either alone or with soluble anti -CD28 mAb ( 2.5 g /mL ). All additives were included at the start of the culture period with a final culture volume of 200 l in round -bottom 96 -well microtiter plates. The plates were incubated at 378C in 5% CO 2 /95% air. After 20 hours, SNs were harvested and analyzed for IL -2 secretion using a commercially available ELISA ( Diaclone, Besançon Cedex, France ). The number of viable cells was measured after three days using CellTiter 96
1 Aqueous one solution cell proliferation assay (Promega, Madison, WI ). 
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Results and discussion
A chimeric gene consisting of the extracellular domain of human B7 -1 ( residues 1 to 225 ) fused to a five -linker diabody that recognizes the human CEA was constructed (B7-CEA ) ( Fig 1A ) and cloned into the mammalian expression vectors pCEP4 and pREP9 to obtain the plasmids pLAV32 and pR32, respectively. As shown in Figure 2 , active B7 -CEA was secreted into the cell culture SN of human embryonic kidney 293 cells transfected with plasmid pLAV32. Binding specificities of the secreted fusion protein were shown by ELISA. The secreted B7 -CEA molecule bound specifically to CEA, and was recognized by both anti -CD80 ( Fig 2A ) and anti -myc ( data not shown ) mAbs. No binding was detectable on BSA -coated wells (Fig 2) or when the specific mAb (anti -CD80 or anti -myc ) was omitted (data not shown). We next investigated if our genetic construction pLAV32 allowed the secretion of B7 -CEA by a human T-cell line. Selection of Jurkat cells stably transfected with plasmid pLAV32 (JurkatB7 ) resulted in the secretion of functional protein at significant levels ( Fig 2B ) . Expression of B7 -CEA did not interfere with the expression of CD28 that was normal on JurkatB7 cells (data not shown ).
To assess if the secreted fusion protein is capable to act as an efficient costimulatory molecule for T cells in the presence of CEA expressing tumor cells, we performed different cocultures of nontransduced Jurkat cells or stably transfected JurkatB7 cells with CEA -negative ( HeLa ) or CEA -positive ( MKN45 ) tumor cell lines at different effector:target (E:T ) ratios. The TCR signaling was provided by a recombinant bispecific anti -CEAÂanti -CD3 diabody ( CEAxCD3 ). 18 After a 20 -hour incubation period, cellfree SNs were collected to measure the IL -2 secretion by ELISA (Fig 3) . As expected Jurkat cells secreted IL -2 when cocultured with MKN45 cells, due to the activation signal provided by the cross -linking carried out by the recombinant CEAxCD3 diabody ( Fig 3A ) . However, the addition of cell-free SN from cultures of 293 cells stably transfected with plasmid pLAV32 (293.B7 ) containing the B7 -CEA protein (Fig 2A ) resulted in a pronounced and dosedependent enhancement of IL -2 secretion ( Fig 3A ) . Optimal levels of costimulation were in the range 1.5% to 15% ( vol /vol ) of 293.B7-derived SN. Under these conditions, the enhancement of IL-2 secretion was similar to that observed after stimulation of the CD28 molecule with anti -CD28 mAb (data not shown). This effect was not observed when cell -free SN from untransfected 293 cells was used ( not shown). Importantly, the trans -costimulatory effect ( 1) was strictly tumor-specific with non-CEA -expressing HeLa cells unable to costimulate IL -2 secretion ( Fig 3A ) , and ( 2) was evident when very small amounts ( 0.25% ) of 293.B7 -derived SN (vol / vol ) were added to cocultures of Jurkat cells with CEA -positive ( MKN45 ) cells ( Fig 3A ) . This result suggests that a small number of B7 -CEA producer cells are able to secrete high enough levels of the fusion protein to supply effective costimulation.
To investigate the effectiveness of autocrine secretion of B7 À CEA in providing costimulation to cellular antigen we performed cultures in which Jurkat cells or JurkatB7 cells were incubated together with HeLa or MKN45 cells in combination with recombinant diabody. It should be noted that differences in IL -2 secretion levels between different Tcell populations ( parental and transfected Jurkat cell populations) complicate quantitative comparison; therefore, costimulation is expressed as a percentage. As shown in Figure 3B , whereas Jurkat IL -2 secretion is far from reaching the level obtained by optimal stimulation with anti-CD3 plus anti -CD28 mAbs (100% ), JurkatB7 IL -2 secretion reaches and even substantially exceeds ( 130% ) that level at a favorable E:T ratio. This suggests that JurkatB7 cells are receiving a potent costimulatory signal The cis -costimulatory effect was strictly tumor specific ( Fig 3B ) . We next investigated whether the chimeric B7 -CEA could improve the activation of genetically modified T cells expressing a CIR. With this aim we transfected Jurkat cells with a chimeric anti -CEA TCR -based construct ( Fig 1B ) . 24 Selection of Jurkat cells stably transfected with the chimeric TCR construct (JurkatCEA ) resulted in the expression of the CIR on the cell surface ( data not shown ). Transfected Jurkat cells could be activated to secrete IL -2 in a dose -dependent manner, upon antigen-mediated ligation of their CIR by plastic -immobilized CEA (iCEA ) and membrane -bound CEA ( Fig 4A and data not shown ) . IL -2 secretion declined as the antigen concentration increased, and this suppression of IL -2 secretion at high iCEA density was associated with a clear dose -response effect on cell viability (Fig 4B ) . We next investigated the effect of costimulation on this model system. Costimulation was provided by the addition of either anti -CD28 mAb, or cellfree SN from 293.B7 cell cultures. As shown in Figure 4A addition of anti -CD28 mAb resulted in a pronounced enhancement of IL -2 secretion. Optimal levels of IL -2 were seen at intermediate to high concentrations of solid phase CEA ( Fig 4A ) . Importantly, the addition of anti -CD28 mAb preserved cell viability in the range of concentrations studied ( Fig 4B ) . A similar effect was observed when B7 -CEA was present in the culture indicating that it could mimic CD28 -mediated T-cell activation and survival ( Fig 4C ) .
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We next transfected JurkatCEA cells with plasmid pR32 that contains the B7 -CEA gene. Double transfectants resistant to both hygromycin and G418 (JurkatCEA.B7 ) expressed the chimeric anti -CEA -TCR receptor at levels similar to the parental single-transfectant JurkatCEA cells ( data not shown ) and in addition secreted the B7 -CEA protein in a functionally active form ( Fig 4D ) . To assess the effectiveness of autocrine secretion of B7 -CEA in providing costimulation from cellular antigen, JurkatCEA or JurkatCEA.B7 were cultured in the presence of CEAnegative ( HeLa ) or CEA -positive ( MKN45 ) cells at different E:T ratios. After a 20-hour incubation period culture SNs were harvested and analyzed for IL-2 secretion. We found that the secreted fusion protein supplied an effective costimulatory signal that enhances IL-2 secretion without interfering with CIR -mediated cellular activation. Although both JurkatCEA and JurkatCEA.B7 cells secreted IL -2 when stimulated by CEA -expressing MKN45 cells, the percentage of maximal costimulation was higher in JurkatCEA.B7 cells than in JurkatCEA cells ( Fig 4E ) . As above, T-cell activation remained strictly tumor-specific with non-CEA -expressing HeLa cells unable to stimulate IL-2 secretion in either of the T-cell lines ( data not shown ).
In summary we have demonstrated proof of principle for a novel strategy of T-cell activation by autocrine secretion of costimulatory molecules with potential applications in gene therapy or immunotherapy ( Fig 1C ) . We showed that a chimeric B7 -1 antibody fusion protein can be secreted by T cells, even by gene -modified T cells expressing a CEAspecific CIR with the same antibody moiety. The secreted B7 -CEA fusion showed high stability under physiological conditions and bound specifically to the surface of CEAexpressing cancer cells, triggering potent costimulation of T cells in combination with a bispecific antitumorÂanti -CD3 diabody or surface expression of a tumor-specific CIR on the T cell. Our strategy may have advantages over other approaches such as ( 1) the prolonged production of B7 -1 fusion molecules at tumor sites by gene -modified tumorinfiltrating cells rendering tumor cells more immunogenic to the immune system, ( 2) the provision of tumor-specific CD28 -mediated costimulatory signals not only to genemodified (cis -costimulation ) T cells but also to non-genemodified ( trans -costimulation ) T-cell effectors present at the tumor site, and (3 ) the ability to complement and potentially enhance the antitumor potency of current antigen -selective strategies targeting the TCR pathway ( e.g., CIRs and bispecific antibodies ). Tumor-infiltrating cells such as T cells and monocytes, genetically modified to provide self -activation signals in a tumor-specific way, as described here may provide an effective means to initiate or sustain antitumor immune responses or augment immunotherapeutic approaches like tumor vaccines, T-bodies, or bispecific antibodies.
